Robert Simms, MD
Rheumatology · Lebanon, NHNPI 1235101429
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,550 of the $1,710 with a category attached, or 90.7%. Actelion Pharmaceuticals US, Inc. accounts for 97.3% of it on its own, with 1 other manufacturer making up the rest.
Across 3 payments — averaging $569.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$2K
- United Therapeutics Corporation$45
Across 50 payments — averaging $2004.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$37K
- Boehringer Ingelheim$24K
- Genentech, Inc.$13K
- Actelion Pharmaceuticals, Ltd$13K
- EMD Serono, Inc.$6K
- Sanofi US Services Inc.$6K
- plus $1K from 1 others
What the payments were for
- Consulting fees$1,55091%
- Food & beverage$1609%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 2 | $1,664 |
| United Therapeutics Corporation | 1 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPSUMIT$1,550
How this compares
$1,710 in reported general payments places this provider in the 80th percentile of 48 rheumatology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 28 | $243,045 |
| XeljanzTofacitinib Citrate | 25 | $135,426 |
| Orencia ClickjectAbatacept | 18 | $103,041 |
| Enbrel SureclickEtanercept | 12 | $86,938 |
| Taltz AutoinjectorIxekizumab | 13 | $83,135 |
| ActemraTocilizumab | 19 | $57,255 |
| Mycophenolate Mofetil | 55 | $8,276 |
| Hydroxychloroquine Sulfate | 105 | $4,956 |
| MethotrexateMethotrexate Sodium | 139 | $4,002 |
| Colchicine | 25 | $1,957 |
| Prednisone | 137 | $1,100 |
| Pregabalin | 28 | $1,028 |
| Oxycodone Hcl | 37 | $886 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $833 |
| Gabapentin | 30 | $831 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Lebanon
- William RigbyLebanon$83K
- Lindsey MacfarlaneLebanon$3K
- Vivekanand TiwariLebanon$2K
- Nicole OrzechowskiLebanon$1K
- Scott PompaLebanon$629
- Daniel AlbertLebanon$234
- Christopher BurnsLebanon$34
- Stephanie MathewLebanon$0
- Alicia ZbehlikLebanon$0
- Lin BrownLebanon$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.